Director, Translational Medicine, Imaging

Who is BlueRock? BlueRock Therapeutics, a wholly‑owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company using its unique CELL+GENE™ platform to direct cellular differentiation and genetically engineer cells to create a new generation of cellular medicines that address large patient populations suffering from neurological, cardiovascular, and immunology diseases. The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel CELL+GENE™ platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology. What Are We Doing? Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit. We are passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with treatment options. We are seeking individuals who are collaborative, thrive in a fun and dynamic culture, and are steadfast in the commitment to advance cutting‑edge cellular therapies to impact patients’ lives. Description of Position: It continues to be an exciting time for BlueRock Therapeutics as the company advances cutting‑edge cellular therapies to positively impact patients’ lives across multiple disease areas. The Director of Imaging and Biomarkers, Translational Medicine, will be expected to take on a highly visible role with internal and external stakeholders through the management of the imaging protocols and biomarkers leveraged in BlueRock’s clinical development programs. The Director of Imaging and Biomarkers will leverage their expertise in CNS, ophthalmic and inflammation imaging to advance the company’s development pipeline by working closely with program leads and other subject matter experts. The position will be based in Cambridge, Massachusetts. Responsibilities As a critical member of the Translational Medicine team, the Director of Translational Medicine (Imaging) will leverage their expertise in CNS to: Develop translational strategies designed to support clinical development plans, the regulatory path, and product commercialization. Lead the development and implementation of translational imaging strategies in support of clinical proof‑of‑mechanism, patient stratification, dose selection. Serve as the neuroimaging lead on cross‑functional program teams. Partner with Research to discover and characterize novel imaging biomarkers in preclinical studies. Develop imaging methods and analytically validate imaging tools for clinical use. Implement clinical biomarkers and ensure biomarker‑driven decision‑making across all phases of drug development. Lead cross‑functional imaging governance (e.g., Imaging Steering Committee) advancing the use of imaging biomarkers to enable demonstration of disease‑modifying effects. Deliver subject matter expertise with respect to clinically advanced techniques in MRI, PET, SPECT, HRCT and other modalities as needed. Oversee CRO vendor/partners ensuring that they optimally execute clinical and preclinical imaging projects in the US, Canada, and other regions of interest. Provide support for the Business Development organizations as needed on diligence efforts. Minimum Requirements PhD, MD, PharmD, or equivalent degree in Neuroscience, Biomedical Imaging, Radiology, or related discipline. 6+ years of industry experience in translational medicine, imaging sciences, or clinical development. Deep expertise in clinical and translational neuroimaging, including MRI and PET methodologies. Must have direct experience managing imaging protocols in the conduct of clinical trials (endpoints, inter‑site harmonization, imaging core lab oversight, etc.). Specific experience with imaging endpoints for early‑stage clinical development in CNS, ophthalmic and inflammatory diseases is desired. $210,000 - $225,000 a year #J-18808-Ljbffr BlueRock Therapeutics